Methyl aminolevulinate (MAL) is a drug used as asensitizer inphotodynamic therapy. It is aprodrug that is metabolized toprotoporphyrin IX. It is marketed asMetvix.
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Multum Consumer Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C6H11NO3 |
| Molar mass | 145.158 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Metvix is developed byPhotocure andGalderma has bought all rights to Metvix.[1]
Approvals and indications
edit
Methyl aminolevulinate is approved in New Zealand for treatment ofbasal cell carcinoma.[2]
It is now approved in many countries and has been used to treat non-melanomaskin cancer (includingbasal cell carcinoma).[3]
It has some advantages overLevulan.[4]
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients.[5]
References
edit- ^"Photocure Divests Metvix to Galderma for EUR 51 Million". Archived fromthe original on 2011-02-07. Retrieved2010-09-10.
- ^Ngan V (2003)."Methyl aminolevulinate photodynamic therapy (MAL PDT)".DermNet NZ.
- ^"New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment".EurekAlert!. 2006.
- ^O'Connor AE, Gallagher WM, Byrne AT (2009)."Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy".Photochemistry and Photobiology.85 (5):1053–74.doi:10.1111/j.1751-1097.2009.00585.x.PMID 19682322.S2CID 205950773.
- ^"Concerns raised over ALA skin cancer cream as patients recount 'horrendous' pain". Australian Broadcasting Corporation. 16 November 2013.